Indian Pharma Market registers 11 percent growth in April: IQVIA
New Delhi: The Indian Pharmaceutical Market (IPM) has reported double-digit growth of 11 percent for the month of April 2023, according to IQVIA.On a four-year basis, the Total Sales Audit (TSA) valued at Rs 202,395 crore with growth of 10 percent as of Moving Annual Turnover (MAT) April and Rs 17,799 crore for April month with growth of 11 percent was recorded. On the other hand, the...
New Delhi: The Indian Pharmaceutical Market (IPM) has reported double-digit growth of 11 percent for the month of April 2023, according to IQVIA.
On a four-year basis, the Total Sales Audit (TSA) valued at Rs 202,395 crore with growth of 10 percent as of Moving Annual Turnover (MAT) April and Rs 17,799 crore for April month with growth of 11 percent was recorded. On the other hand, the Stockist Sales Audit (SSA) has been valued at Rs 71,260 crore with growth of 9 percent as of MAT April and Rs 15,058 crore for April month with growth of 11%.
As per the report, Respiratory followed by Anti-infectives posted highest growth at 29 percent and 25 percent respectively. Last month, in March, Anti-infectives was ahead and registered at 50 percent, however, this month it slipped to second position after anti-infectives.
Meanwhile, performance of anti-diabetic showed single digit growth at 5 percent valued at Rs 1,601 crore.
Pharma firms including Sun Pharma, Mankind Pharma, Intas and Torrent have shown improvement in market share for the month of April as compared to March 2023. Abbott, Cipla, Alkem, Lupin, Macleods and Aristo reflected dip in the market share for the month as compared to March, 2023.
Among top ten firms for the month, Mankind and Aristo posted highest growth at 11 percent each, valued at Rs 809 crore and Rs 537 crore respectively on Month level, while on MAT level, Intas Pharma has reflected the highest growth at 16 percent followed by Alkem and Macleods at 15 percent each.
In the month of April, 2023 (in comparison to March), among the top 25 companies, Sun Pharma has maintained its top position in the IPM with a market share of 8%. Intas, Torrent, USV and Eris improved by 1 rank each to reach 6th, 7th,15th & 23rd positions, respectively. Sanofi improved by 2 ranks to reach 18th position.
Mixtard identified itself as the topmost brand with 76 crores of sales and market share of ~0.43% for the month. Among top 10 brands, Monocef has shown highest growth followed by Foracort and Augmentin for the month.
Among the top 25 products as per Apr'23 Month (in comparison to Mar'23 Month), Mixtard gained 1 rank and is at number 1 position at month with -1% growth. Mixtard, Glycomet-GP, Foracort, Thyronorm, Udiliv and Novomix gained 1 rank to secure 1st, 2nd,3rd,9th,17th & 25th position, respectively.
Amongst the top 10 brands, highest growth is observed by Monocef and Foracort with a growth of 35% & 33% each respectively. Pan-D and Manforce gained 2 ranks to secure 15th & 20th position respectively with a growth of 8% & 42% each respectively.
As per the IQVIA data, Ultracet gained 3 ranks to secure 24th position with a growth of 4%. Shelcal gained 5 ranks to secure 23rd position with a growth of 6%. Dexorange gained 6 ranks to secure 14th position with a growth of 2%. Liv-52 & Aciloc gained 7 ranks to secure 8th & 18th position with a growth of 1% & 37%. Electral gained 19 ranks to secure 5th position with a growth of 1%. Indian companies has registered growth of 12% whereas MNC’s registered a growth of 8% for the month. Acute has shown growth of 12% whereas Chronic has shown growth of 10% for the month.
An insight of top therapy trends showed as Cilnidipine posting the highest growth of 20%, in cardiac segment. In AI, Azithromycin Oral Solids has posted high growth of 75%. Pantopr.+ Domperid.is the top contributing subgroup in GI therapy with value of around 138 Crore growing at 9%.
In Anti diabetic, Fast Acting subgroup has posted highest growth of 10% while Glime+Metformin the largest sub group grew at 6%.
In VMN therapy, food supplements came up as the top contributing subgroup with 189 crore and growth of 8%. In Respiratory market, cough prep is observed to be top contributing one with 210 Crore of sales and growth of 57%.
Further, in pain market, paracetamol oral solids, liquids & inj contributed ~ 179 Crore of sales with 71%,15% & 30% growth, respectively. Emollients protectives registered highest sales of 131 Crore in derma market with 18% growth while the highest growth of 29% is observed in Sunscreens.
In Neuro therapy, levetiracetam is the top valued subgroup with 88 Crores of sales and 9% growth. In Gynaec therapy, conv iron solids, liquids and inj. together have contributed ~304 Crore of sales to the entire therapy
Amongst the top Gynae therapies, Mifepristone+Misoprostol has posted highest growth of 26%.
Key Changes
Total number of SKUs with PTR changes in Apr'23 are 2374. Among the top 50 brands of the industry, PTR changes reflected in SKUs of the following brands : Budecort, Foracort, Seroflo, Telma, Azithral, Clavam, Dexorange, Glycomet-Gp, Levipil, Manforce, Monocef, Pan-D, Pantop, Shelcal, Taxim-O, Ultracet, Zifi
26 Corporates and Labs; and 1748 new packs were introduced in April, 2023 dataset, while 4 brand transfers were registered.
